Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-22
2008-11-11
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S218000, C514S227800, C514S232800, C514S253050, C540S575000, C544S060000, C544S128000, C544S363000, C546S139000, C546S148000
Reexamination Certificate
active
07449477
ABSTRACT:
The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
REFERENCES:
patent: 4525589 (1985-06-01), Hidaka et al.
patent: 4678783 (1987-07-01), Hidaka et al.
patent: 5747507 (1998-05-01), Ikegaki et al.
patent: 0 520 336 (1992-06-01), None
patent: 06 100540 (1994-04-01), None
patent: WO 01/64238 (2001-09-01), None
patent: WO 01/91754 (2001-12-01), None
patent: WO 02/50019 (2002-06-01), None
patent: WO 02/083064 (2002-10-01), None
patent: WO 2004/094386 (2004-11-01), None
patent: WO 2005/011697 (2005-02-01), None
Reuveni, Hadas, et al., “Toward a PKB Inhibitor: Modification of a Selective PKA Inhibitor by Rational Design,” Biochemistry, vol. 41, No. 32, pp. 10304-10314 (2002); XP002267237.
Barda David Anthony
Henry, Jr. Kenneth James
Huang Jian-ping
Joseph Sajan
Lin Ho-Shen
Davis Zinna N
Desai Manisha A.
Eli Lilly and Company
Hostettler Danica
LandOfFree
7-phenyl-isoquinoline-5-sulfonylamino derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-phenyl-isoquinoline-5-sulfonylamino derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-phenyl-isoquinoline-5-sulfonylamino derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034103